{"url_path":"/sec/arct/8-k/2026-07-02/item-1-01","section_key":"item-1-01","section_title":"Item 1.01 **","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-07-02","source_url":"https://www.sec.gov/Archives/edgar/data/1768224/0001193805-26-000910-index.html","accession_number":"0001193805-26-000910","cik":"0001768224","ticker":"ARCT","issuer_name":"Arcturus Therapeutics Holdings Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1768224/0001193805-26-000910-index.html","primary_entity_key":"0001768224","primary_entity_name":"Arcturus Therapeutics Holdings Inc."},"word_count":455,"has_tables":true,"body_markdown":"**Item 1.01**\n**Entry Into a Material Definitive Agreement.**\n\n \n\nOn June 26, 2026, Arcturus Therapeutics, Inc. (“Arcturus”),\na wholly-owned subsidiary of Arcturus Therapeutics Holdings Inc., a Delaware corporation (the “Company”), entered into\na series of agreements with Thermo Fisher Scientific Inc. (“Thermo Fisher”) and certain of Thermo Fisher’s affiliates\nto establish a strategic collaboration for the provision of contract development and manufacturing organization (“CDMO”)\nand contract research organization (“CRO”) services in connection with the development of ARCT-032, the Company’s\ninvestigational mRNA therapeutic for cystic fibrosis (“CF”). The collaboration is structured through (i) a Master Services\nAgreement (the “MSA”) between Thermo Fisher and Arcturus and (ii) a Project Addendum for Development Services between\nPatheon UK Limited, a Thermo Fisher affiliate (“Patheon”), and Arcturus (the “Project Agreement”,\nand together with the MSA, the “Transaction Documents”).\n\n \n\n**Master Services Agreement**\n\n \n\nThe MSA establishes the framework under which Thermo Fisher and its\naffiliates will provide CRO and CDMO services to Arcturus from time to time pursuant to the Project Agreement and any additional individual\nproject addendums. CRO services will be provided through PPD, Inc., Thermo Fisher’s affiliated contract research organization (“PPD”),\nand CDMO services will be provided through Thermo Fisher’s Pharma Services division. Under the MSA, Thermo Fisher will contribute\nup to $40 million of clinical manufacturing services for ARCT-032, and Arcturus will engage PPD for up to $40 million in CRO services.\nUpon regulatory approval of ARCT-032, Thermo Fisher would receive exclusive commercial manufacturing rights for the product for a specified\nduration, on terms to be set forth in a definitive commercial supply agreement to be negotiated in good faith by the parties. Arcturus\nmay engage an alternative manufacturer only if Thermo Fisher is unable to supply, limited solely to the quantities and duration necessary\nto address the supply shortfall. The MSA has an initial term of five years from the effective date and automatically renews for successive\none-year periods unless either party provides at least 90 days’ prior written notice of non-renewal.\n\n \n\n**Project Agreement**\n\n \n\nUnder the Project Agreement, the services to be provided include technical\ntransfer, engineering batches, manufacture of clinical trial materials, manufacture of process performance qualification batches, open-label\nextension batches, drug product fill and finish, product release, and stability studies. The Project Agreement remains in effect from\nits effective date until the completion of all services or earlier termination under the MSA.\n\n \n\nThe foregoing descriptions of the MSA and the Project Agreement, do\nnot purport to be complete and are qualified in their entirety by reference to the full text of each such agreement, copies of which the\nCompany intends to file with the Securities and Exchange Commission (the “SEC”) as exhibits to the Company’s Quarterly\nReport on Form 10-Q for the quarter ending June 30, 2026."}